Paul Goepfert is an Infectious Disease physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
619 19th Street South
Birmingham, AL 35233
Telephone
205-934-6600Registry record last updated 29 Jun 2023.
Clinical trials
- Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20221 payment
- Janssen Scientific Affairs, LLCProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.3%Gabapentinoids43.4%Gabapentin100%Part D<11 patientsOpioid Agonist18.9%Morphine Sulfate Er52%Oxycodone Hcl48%Part D<11 patientsCardiovascular
27.9%Calcium channel blocker17.2%Amlodipine Besylate100%Part D<11 patientsStatin10.7%Atorvastatin Calcium100%Part D<11 patientsRespiratory
9.8%Opioid Agonist9.8%Hydrocodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
15 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- Onco-immunologic factors contributing to OPSCC among people living with HIV
University of Alabama at Birmingham
FY2026$697,916R01DE033864
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”